Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

The role of mesenchymal stem cells in the occurrence, development, and therapy of hepatocellular carcinoma

Zhang X., Li N., Zhu Y., Wen W.

Narrative Review on Hip, published in Cancer Med (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cancer Med (2022)
Reported sample size
—
Source database
Europe PMC
PMID
34981659
PMCID
PMC8855904
DOI
10.1002/cam4.4521
Citations
24

Abstract (original English)

Hepatocellular carcinoma (HCC) is the most common type of liver malignant tumor, with high recurrence and mortality rates. Mesenchymal stem cells (MSCs) are multipotent cells that can be recruited into the tumor microenvironment (TME). What is known, TME plays a vital part in tumor progression. In recent years, accumulating studies have found that MSCs have a dual role of promotion and inhibition in the occurrence and development of HCC. In this review, we analyzed the role of MSCs in TME and summarized the relationship between MSCs and liver cancer stem cells, the molecular signaling pathway mechanisms of MSCs promoting and inhibiting HCC, and the latest research progress of MSCs in the treatment of HCC.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsHumansCarcinoma, HepatocellularLiver NeoplasmsSignal TransductionTumor Microenvironment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research